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Phosphatidylinositol transfer protein-α in platelets
is inconsequential for thrombosis yet is utilized for
tumor metastasis
Liang Zhao1, Chelsea L. Thorsheim1, Aae Suzuki1, Timothy J. Stalker 1, Sang H. Min1, Lurong Lian1,
Gregory D. Fairn 2, Shamshad Cockcroft 3, Amy Durham4, Sriram Krishnaswamy5 & Charles S. Abrams1,6
Platelets are increasingly recognized for their contributions to tumor metastasis. Here, we
show that the phosphoinositide signaling modulated by phosphatidylinositol transfer protein
type α (PITPα), a protein which shuttles phosphatidylinositol between organelles, is essential
for platelet-mediated tumor metastasis. PITPα-deﬁcient platelets have reduced intracellular
pools of phosphoinositides and an 80% reduction in IP3 generation upon platelet activation.
Unexpectedly, mice lacking platelet PITPα form thrombi normally at sites of intravascular
injuries. However, following intravenous injection of tumor cells, mice lacking PITPα develop
fewer lung metastases due to a reduction of ﬁbrin formation surrounding the tumor cells,
rendering the metastases susceptible to mucosal immunity. These ﬁndings demonstrate that
platelet PITPα-mediated phosphoinositide signaling is inconsequential for in vivo hemostasis,
yet is critical for in vivo dissemination. Moreover, this demonstrates that signaling pathways
within platelets may be segregated into pathways that are essential for thrombosis formation
and pathways that are important for non-hemostatic functions.
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P latelets are best known for their contribution to hemostasis,but several lines of evidence indicate that they also contributeto tumor metastasis. For example, elevated platelet counts are
associated with a poor prognosis in patients with cancer, whereas
low platelet counts are associated with reduced metastatic burden1–6.
Additionally, studies suggest that platelets assist tumor cell adhesion
to the vasculature and enhance tumor cell growth. Aberrant platelet
activation and aggregation are frequently found in the vasculature of
cancer patients, especially in patients with metastatic tumors7–10.
Furthermore, studies that use genetically engineered mice with
altered platelet functions, or those that use pharmacologic inhibitors
against platelet activation, show that platelets can protect circulating
tumor cells from elimination by the immune system and therefore
support further metastasis11, 12.
Platelet-mediated vascular plug formation is critically depen-
dent on phosphatidylinositol signaling, although it only com-
prises about 8% of the phospholipids contained in a typical
mammalian cell13–17. The phosphatidylinositol head group is
capable of being differentially phosphorylated, generating a
family of seven functionally distinct phospholipids, called phos-
phoinositides (PtdIns)13. Intracellular PtdIns concentrations are
tightly regulated both in time and space, and the distribution
between the various PtdIns species changes within seconds after
agonist stimulation. PtdIns generation is a key cellular event in all
eukaryotic cells, including in platelets, where it regulates integrin
activation, actin assembly, and secretion13, 14. However, whether
platelet PtdIns signaling contributes to platelet-mediated tumor
metastasis is unknown.
Since PtdIns contain hydrophobic acyl side chains that render
them insoluble in the aqueous cytoplasm, they are assumed to
always be associated within a lipid bilayer. Curiously, the sites of
synthesis of different PtdIns are on the surfaces of distinct cellular
organelles. For example, phosphatidylinositol is synthesized in
the endoplasmic reticulum (ER), while PtdIns(4)P is synthesized
on the surface of internal granules, such as on endosomes, and
PtdIns(4,5)P2 is synthesized on the cell membrane18, 19. This
implies that the sequential synthesis of polyphosphorylated
phosphatidylinositols, such as PtdIns(4,5)P2, begins with
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Fig. 1 PITPα mediates PtdIns synthesis and IP3 production in mouse platelets. a Quantiﬁcation of immunoblot demonstrates the types of class I PITP
expressed in platelet lysates using isoform-speciﬁc antibodies. Shown is the relative abundance of individual PITP isoforms in platelets from wild-type mice
when normalized to recombinant PITP protein standards (n= 3 mice per group; error bars are standard deviation (s.d.)). b Schematic representation of the
conditional targeting strategy. Exons 8, 9, and 10 were targeted by the insertion of loxP recombination sites to generate Pitpα ﬂoxed alleles (Pitpαﬂ/ﬂ).
c Immunoblot of platelet lysate demonstrating the speciﬁc deletion of the PITPα isoform in Pitpαﬂ/ﬂPf4-Cre+ platelets. d CBC analyses show decreased
platelet count in Pitpαﬂ/ﬂPf4-Cre+mice compared to their littermate controls (n= 3 mice per group; error bars are s.d.; *p< 0.05, unpaired Student’s t-test).
e PtdIns synthesis in thrombin-stimulated platelets derived from Pitpαﬂ/ﬂPf4-Cre− and Pitpαﬂ/ﬂPf4-Cre+ mice. Pooled analysis of experiments shows the
effect of the loss of PITPα on PtdIns(4)P and PtdIns(4,5)P2 generation following thrombin stimulation at 1 U/ml (n= 3 mice per group; error bars are s.d.;
*p< 0.05, unpaired Student’s t-test). f The effect on IP3 production by the loss of PITPα was analyzed. IP3 production was impaired even at the earliest
analyzed time point (n= 3 mice per group; error bars are s.d.)
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phosphatidylinositol production in the ER, and the intermediate
isoforms are trafﬁcked between the organelles before ﬁnal
production in the plasma membrane. We and others have shown
that the sequential enzymatic steps required for higher-order
phosphoinositide synthesis occur within seconds14, 20, 21.
Consequently, a mechanism for rapidly transferring
phosphatidylinositol between membranes is required.
Phosphatidylinositol transfer proteins (PITP) facilitate the
transfer of insoluble phosphatidylinositol from one membrane to
another in vitro. They achieve this by binding and encompassing
the fatty acid side chains of phospholipids and transporting the
phospholipids throughout the cytoplasm. Mammalian cells con-
tain both PITPα and PITPβ isoforms, which are small, highly
conserved, and ubiquitously expressed single PITP domain
soluble proteins. Ablation or knock down of PITPα impairs
viability, membrane trafﬁcking, and cytokinesis22–25. Because the
phosphatidylinositol transfer activity of PITPα is required for the
synthesis of phosphoinositides and for the regulation of PtdIns
kinases, it has been assumed that PITPα is essential for all of the
signaling events that utilize phosphoinositides, including
platelets26, 27.
In this study, we investigate whether platelet-speciﬁc disrup-
tion of phosphatidylinositol metabolism mediated by PITPα
impacts hemostatic and non-hemostatic functions of platelets in
tumor dissemination. Our study unexpectedly shows that PITPα,
the major PITP isoform in murine platelets, is inconsequential for
hemostasis in vivo. However, PITPα-mediated PtdIns(4,5)P2
synthesis and IP3 production in platelets are critical to promote
platelet-mediated lung metastasis of intravenous injected tumor
cells. We demonstrate that signaling pathways required for
thrombosis formation may be independent from those pathways
required for non-hemostatic platelet functions, such as those
pathways that regulate interactions with immune cells.
Results
Conditional deletion of the PITPα in murine platelets. Plate-
lets, like other mammalian cells, contain both the PITPα and
PITPβ isoforms. We observed that the PITPα isoform is
approximately six-fold more abundant than PITPβ in murine
platelets (Fig. 1a and Supplementary Fig. 1). To determine the
role of PITPα in platelets, we genetically deleted PITPα from
murine platelets and megakaryocytes (Fig. 1b). To accomplish
this, the PITPα gene was conditionally targeted at the domain
previously demonstrated to be essential for the phosphatidyli-
nositol transfer function of PITPα22, 28, and the resultant mice
were crossed with transgenic mice expressing the CRE recombi-
nase, whose expression was controlled by the megakaryocyte-
speciﬁc platelet-factor-4 promoter (Pf4-Cre)29. We found no
detectable full-length or truncated forms of PITPα protein in the
lysates of platelets derived from Pf4-Cre-positive PITPα ﬂoxed
mice (Pitpαﬂ/ﬂPf4-Cre+) by immunoblotting. The PITPβ protein
expression remained unchanged in the Pitpαﬂ/ﬂPf4-Cre+
mice, with similar expression levels to those in the control
Pitpαﬂ/ﬂPf4-Cre− mice (Fig. 1c).
The Pitpαﬂ/ﬂPf4-Cre+ mice were grossly normal, with body
weight, organ morphology, leukocyte counts, and hemoglobin
levels that were indistinguishable from the littermate controls
(Pitpαﬂ/ﬂPf4-Cre− mice) (Supplementary Fig. 2). Although there
was a 15% decrease in platelet counts in the Pitpαﬂ/ﬂPf4-Cre+
mice (Fig. 1d), it is still within normal range. The mice grew to
adulthood without any observable increase in spontaneous
hemorrhage, thrombosis, or mortality.
PITPα is essential for platelet phosphoinositide signaling. To
study the role of PITPα in the synthesis of phosphoinositides in
platelets, we analyzed the concentration of speciﬁc phosphoino-
sitides within platelets from Pitpαﬂ/ﬂPf4-Cre+ mice by using thin-
layer chromatography (TLC). These platelets had a 34.7%
reduction of PtdIns(4)P and a 41.2% reduction in PtdIns(4,5)P2
at resting conditions (Fig. 1e). When stimulated with thrombin,
the deﬁciency remained in PITPα-null platelets (30.5% reduction
of PtdIns(4)P levels and 34.1% reduction of PtdIns(4,5)P2 levels),
demonstrating that PITPα is required for the synthesis of higher-
order phosphoinositides in platelets.
Following thrombin stimulation, PtdIns(4,5)P2 in platelets is
hydrolyzed by phospholipase C to generate second messengers,
such as IP3. We analyzed IP3 synthesis in thrombin-stimulated
platelets that lack PITPα, in order to test whether phosphoinosi-
tide transfer is required for rapid IP3 production. Although the
baseline IP3 level in platelets derived from Pitpαﬂ/ﬂPf4-Cre+ mice
was not different from the control mice, the IP3 generation
following thrombin stimulation was blunted by approximately
80%, an effect that was apparent as early as 5 s after agonist
stimulation (Fig. 1f). Furthermore, the intracellular calcium levels
were lower in Pitpαﬂ/ﬂPf4-Cre+ platelets following thrombin
stimulation (Supplementary Fig. 3). These data indicate that
PITPα-mediated synthesis of PtdIns(4,5)P2 contributes to IP3
formation, which occurs within seconds after agonist stimulation.
It is noteworthy that although PITPα is only required for the
synthesis of approximately 40% of platelet PtdIns(4,5)P2 (Fig. 1e),
it is required for a much larger percentage of the IP3 that is
synthesized after agonist stimulation (Fig. 1f). Since IP3 is derived
entirely from PtdIns(4,5)P2, these results suggest that PITPα may
be required for the production of the speciﬁc pool of PtdIns(4,5)
P2 that is utilized for IP3 formation.
PITPα is inconsequential for platelet aggregation. To deter-
mine whether the deletion of PITPα impacts platelet function, we
compared the ex vivo aggregation of PITPα-null platelets with
those of the littermate controls using light transmission aggre-
gometry. PITPα-null platelets aggregated normally in response to
the platelet agonists that include thrombin, collagen, ADP, PMA,
and U46619, at all dosages tested (Fig. 2a and Supplementary
Table 1). Ex vivo platelet αIIbβ3 integrin activation (JON/A) and
secretion (P-selectin) measured by ﬂow cytometry were also
normal (Supplementary Table 2). These results were unexpected
given the defects in phosphoinositide synthesis and second
messenger formation observed in PITPα-null platelets.
To determine whether these results also pertained to platelet
function in vivo, we investigated whether platelets lacking PITPα
formed thrombi normally by using three established murine
models. First, we analyzed whether the loss of PITPα in platelets
affected tail bleeding times. By analyzing a large number of
animals (90 Pitpαﬂ/ﬂPf4-Cre+ mice and 40 Pitpαﬂ/ﬂPf4-Cre−
mice), we could demonstrate that the bleeding time was longer
in the Pitpαﬂ/ﬂPf4-Cre+ mice (median time 58.5 s) when
compared with the Pitpαﬂ/ﬂPf4-Cre− mice (median time= 29.0
s, p< 0.005, unpaired Student’s t-test; Fig. 2b). However, the
average blood volume lost was comparable between the Pitpαﬂ/
ﬂPf4-Cre+ and Pitpαﬂ/ﬂPf4-Cre− mice (Supplementary Fig. 4).
Since the absolute differences in bleeding time were small, there
was a large amount of variability in this assay even within mice of
the same genotype, and the results may be inﬂuenced by platelet-
independent factors such as coagulation and vascular muscle
tone, we analyzed the ability of these mice to form intravascular
thrombi using several alternative methods.
Platelet-mediated in vivo thrombosis were directly tested using
a FeCl3 carotid injury model by analyzing thrombus formation in
response to a chemical injury. Using this method, we could not
identify any difference in the rate of thrombus formation between
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Pitpαﬂ/ﬂPf4-Cre+ mice and Pitpαﬂ/ﬂPf4-Cre− mice (Fig. 2c). We
also analyzed thrombosis formation and platelet α-granule
secretion in response to a laser-induced vascular injury30. As
shown in Fig. 2d, the loss of platelet PITPα did not signiﬁcantly
decrease platelet accumulation at the injured vessel wall.
Similarly, PITPα-null platelets translocated normal amounts of
P-selectin onto their surface (Fig. 2e), indicating that these
genetically modiﬁed platelets have no obvious defect in α-granule
secretion in vivo, conﬁrming the previous ex vivo secretion data.
Taken together, our studies demonstrate that the predominant
platelet PITP isoform, PITPα, does not contribute signiﬁcantly to
platelet-mediated hemostasis ex vivo or in vivo.
Platelet PITPα is essential for melanoma cell metastasis. In
addition to hemostasis, platelets have been implicated in other
processes, such as the formation of tumor metastases31. To
determine whether PITPα-mediated phosphoinositide
a
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Fig. 2 Platelet PITPα is inconsequential for hemostasis. a Platelets lacking PITPα were analyzed after agonist stimulation in a Lumi-Dual aggregometer. Platelets
derived from Pitpα knockout mice exhibited essentially no defect in aggregation in response to all analyzed agonists. b Tail bleeding times in mice lacking PITPα.
Pitpαﬂ/ﬂPf4-Cre+ mice (n= 90) and Pitpαﬂ/ﬂPf4-Cre− mice (n= 40) were analyzed for the duration of their tail bleeding. The median difference was 29.5 s
(*p<0.005, unpaired Student’s t-test). c Carotid arteries of Pitpαﬂ/ﬂPf4-Cre+ mice (n= 5) and Pitpαﬂ/ﬂPf4-Cre− mice (n= 7) were subjected to a ferric chloride
induced injury, and blood ﬂow was monitored as a measure of thrombus formation. The time-to-form occlusions (TTFO) of the blood ﬂow were not found to be
signiﬁcantly different between mice lacking PITPα in their platelets and the control mice. Statistical analysis was performed using an unpaired Student’s t-test.
Error bars are s.d. (d, e). Laser-induced injury model demonstrates normal in vivo thrombosis and platelet secretion in Pitpαﬂ/ﬂPf4-Cre+ mice. Shown is platelet
accumulation (d) and P-selectin exposure (e) in response to a laser-induced injury to mouse cremaster arterioles. The area under the area/time curve and peak
area are shown. The graphs show the means for n= 15 injuries in three Pitpαﬂ/ﬂPf4-Cre− mice and n= 25 injuries in three Pitpαﬂ/ﬂPf4-Cre+ mice. Statistical
analysis was performed using an unpaired Student’s t-test. Shown are the means± s.d. for all ﬁgure panels
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Fig. 3 Loss of PITPα in platelets impairs tumor metastasis formation. a The lungs derived from Pitpαﬂ/ﬂPf4-Cre− and Pitpαﬂ/ﬂPf4-Cre+ mice harvested
2 weeks after tail vein injection with B16F10 melanoma cells. Shown are representative lungs. The number of tumor nodules on the lung surface was
reduced in Pitpαﬂ/ﬂPf4-Cre+ mice when compared with Pitpαﬂ/ﬂPf4-Cre− controls. Scale bar is 10 mm. *p< 0.0001, unpaired Student’s t-test. b Similarly,
3 weeks after tumor injection, the lungs of the Pitpαﬂ/ﬂPf4-Cre+ mice contained less metastasis than the Pitpαﬂ/ﬂPf4-Cre− mice as indicated by their
weights. Scale bar is 10 mm. **p< 0.0001, unpaired Student’s t-test. c H&E staining of tumors in lung tissue sections at 3 weeks after tumor injection show
no signiﬁcant ﬁbrosis or hemorrhage. Black scale bars represent 100 µm. d Shown are serial platelet counts analyzed after tumor injection. Control mice
have an abrupt decrease in their platelet counts 3 h after tumor injection. This reduction was markedly blunted in the Pitpαﬂ/ﬂPf4-Cre+ mice (n= 6 for each
genotype, ***p< 0.05, unpaired Student’s t-test). Shown are the means± s.d. e H&E staining for lung tissues at 3 h after tumor cell injection demonstrated
tumor-induced thrombi formation within lung tissue. The stars indicate the tumor-induced thrombi. Black scale bars represent 200 µm. f Quantiﬁcation of
CD41-positive thrombi formation observed within lung tissue of the Pitpαﬂ/ﬂPf4-Cre+ mice (n= 4) and the Pitpαﬂ/ﬂPf4-Cre− control mice (n= 5).
***p= 0.02, unpaired Student’s t-test. Error bars are s.d. g Immunohistochemistry analysis of tumor-induced thrombi in lung tissues at 3 h after tumor
injection staining for CD41 (platelet marker) and TRP1 (B16F10 tumor cells). The arrows indicate the tumor cells. This demonstrates that the tumor cells are
coated with large clusters of platelets in the Pitpαﬂ/ﬂPf4-Cre− mice. This phenomenon was less frequently found in the Pitpαﬂ/ﬂPf4-Cre+ mice. Black scale
bars represent 100 μm. h Ex vivo adhesions of platelets on tumor cell layers indicate impaired interactions between Pitpαﬂ/ﬂPf4-Cre+ platelets and tumor
cells. N= 3 mice per group. Shown are the mean± s.d. for all ﬁgure panels
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metabolism in platelets is involved in tumor dissemination, we
utilized a well-characterized B16F10 melanoma model of tumor
metastasis32. In this model, the quantity of tumor foci were
measured following intravenous injection of B16F10 melanoma
cells in mice. Two weeks after tumor cell injection, Pitpαﬂ/ﬂPf4-
Cre+ mice developed 50% fewer tumor foci on the surface of their
lungs as compared to the littermate controls (p< 0.0001,
unpaired Student’s t-test; Fig. 3a). Furthermore, 3 weeks after
tumor cell injection, the lung weights of freshly dissected
Pitpαﬂ/ﬂPf4-Cre+ mice were 50% lower than those harvested from
Pitpαﬂ/ﬂPf4-Cre− mice (p< 0.0001, unpaired Student’s
t-test; Fig. 3b). The histology showed that compared to the
Pitpαﬂ/ﬂPf4-Cre+ mice, Pitpαﬂ/ﬂPf4-Cre− mice did not develop
more hemorrhages or ﬁbrosis in their lungs at 3 weeks after
tumor injection (Fig. 3c). This suggested that the increased lung
weight in the control mice is due to the metastatic burden of the
tumors. Thus, these data indicate that platelet PITPα contributes
to the dissemination of intravenous injected B16F10 melanoma
cells.
To determine whether this observation was limited to B16F10
melanoma cells, Lewis lung carcinoma (LLC) cells also were
injected intravenously, and metastasis formation was evaluated at
2 weeks after tumor injection by counting the number of tumor
foci on the lung surface (Supplementary Fig. 5). Again, Pitpαﬂ/
ﬂPf4-Cre+ mice developed signiﬁcantly less lung metastasis when
compared to their littermate controls, demonstrating that the
relationship between Pitpαﬂ/ﬂPf4-Cre+ platelets and metastasis
formation is not unique to a speciﬁc tumor cell line.
One possible mechanism by which platelet PITPα contributes
to the dissemination of tumor cells was revealed as control mice,
but not Pitpαﬂ/ﬂPf4-Cre+ mice, quickly become thrombocytope-
nic just 3 h after injecting the tumor cells (Fig. 3d). Platelet counts
in the control mice dropped 70%, while Pitpαﬂ/ﬂPf4-Cre+ mice
had relatively stable platelet counts. Histologic analyses of the
lung tissue at the 3 h time point after tumor cell injection revealed
that Pitpαﬂ/ﬂPf4-Cre+ mice have signiﬁcantly fewer (Fig. 3e, f)
and smaller (Fig. 3g) thrombi in their lungs and pulmonary
vasculature than those found in the control mice.
These data suggest that the formation of thrombi mediated by
platelet PITPα contributes to the thrombocytopenia induced by
the tumor cells.
Previous studies have supported the hypothesis that a direct
in vivo interaction (adhesion) between platelets and tumor cells
can facilitate the implantation of the metastasis and promote
tumor cell invasion and propagation33, 34. To determine whether
PITPα facilitates platelet interactions with B16F10 tumor cells, we
characterized the pulmonary thrombi in more detail by
immunohistochemical staining at 3 h after tumor injection. We
observed that at the core of these thrombi, there were a small
number of tumor cells that were enveloped by platelets. This
shroud of platelet-rich thrombi was much larger in the control
mice than that found in the Pitpαﬂ/ﬂPf4-Cre+ mice (Fig. 3g).
Correspondingly, PITPα-null platelets have signiﬁcantly reduced
ex vivo adhesion to tissue-cultured tumor cells than PITPα
wild-type platelets (Fig. 3h). Together, these ﬁndings suggest that
PITPα in platelets promotes platelet–tumor interaction and
platelet-rich thrombi around tumors.
Tumor-induced thrombin and ﬁbrin generation requires
PITPα. Since hemostatic plugs are often composed of aggregated
platelets that are woven together by ﬁbrin, we analyzed the
tumor-induced thrombi for ﬁbrin by immunohistochemistry. We
observed that the area of ﬁbrin staining was about six-fold higher
in the lung tissues of the control mice when compared to the
Pitpαﬂ/ﬂPf4-Cre+ mice (Fig. 4a, b).
Platelets support ﬁbrin formation by providing a negatively
charged surface for the prothrombinase components (FVa and
FXa) to assemble and activate thrombin. This occurs once
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Fig. 4 Loss of PITPα in platelets impairs ﬁbrin deposition and thrombin
generation. a Immunohistochemistry staining for ﬁbrin in tumor-induced
thrombi found in lung tissue at 3 h after tumor injection. The brown color
indicates ﬁbrin deposition within the tissue. Black scale bars represent 100
µm. b Quantiﬁcation of ﬁbrin deposition based on immunohistochemistry
staining. N= 3 mice per group. *p< 0.05, unpaired Student’s t-test. Error
bars are s.d. c Platelets lacking PITPα have an impaired ability to bind
Annexin V ex vivo. The mean values are averaged from four independent
experiments. **p= 0.001, unpaired Student’s t-test. Error bars are s.d. d Ex
vivo TGA initiated by B16F10 tumor cells. Shown is representative kinetics
of thrombin generation in PRP and in PPP. e The endogenous thrombin
potential (ETP) shown is the mean value of total thrombin generated in PRP,
containing either PITPα wild-type platelets (blue bar) or PITPα-null platelets
(red bar). N= 3 mice per group. ***p= 0.01, unpaired Student’s t-test. Error
bars are s.d. f, g Thrombin generation initiated by B16F10 tumor cells in the
presence of agonist TG and calcium ionophore (Iono.). N= 3 mice per
group. *p< 0.05, unpaired Student’s t-test. Error bars are s.d
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platelets ﬂip the negatively charged phospholipid phosphatidyl-
serine from the inner leaﬂet of their cell membrane to the outer
leaﬂet. Using the Annexin V-binding assay to detect phospha-
tidylserine exposure on the outer membrane leaﬂet of platelets,
we observed that Annexin V-binding was signiﬁcantly reduced in
PITPα-null platelets after activation by agonists (thrombin at 0.1
U/ml and collagen at 5 µg/ml) when compared to the control
platelets (Fig. 4c). This indicates that PITPα-null platelets have an
impaired ability to externalize negatively charged lipids on their
surface, which in turn cause defects in prothrombinase complex
assembly, prothrombin activation, and ultimately ﬁbrin
generation.
B16F10 melanoma cells have been shown to express high levels
of tissue factor on their surface, thereby allowing these tumor cells
to initiate the coagulation cascade35. To analyze the contribution
of platelet PITPα to B16F10 melanoma cell-induced prothrombin
activation, we utilized a well-described ﬂuorometric thrombin
generation assay (TGA) to investigate the impact of platelet
PITPα on thrombin generation in platelet-rich plasma (PRP).
When tumor cells were added to PRP that was derived from the
Pitpαﬂ/ﬂPf4-Cre+ mice, we observed 80% less thrombin genera-
tion when compared to PRP derived from the controls (Fig. 4d,
e). This effect was platelet-dependent, since thrombin generation
in platelet poor plasma (PPP) was identical between the two
genotypes. We also analyzed the ability of Pitpαﬂ/ﬂPf4-Cre+
mouse-derived PRP to support thrombin generation when
stimulated by standard tissue factors, and we found similar,
albeit smaller, defects (Supplementary Fig. 6). A peculiar ﬁnding
is that thrombin generation is further suppressed in PRP from
Pitpαﬂ/ﬂPf4-Cre+ mice in comparison to that seen in PPP
(Fig. 4d). Although the explanation for this observation is
unclear, it suggests that platelets lacking PITPα suppress the
ability of tumor cell tissue factor to initiate coagulation.
Under normal circumstances, generation of IP3 within platelets
stimulates a rise in cytoplasmic calcium, which in turn exposes
phosphatidylserine on the surface of platelets to support
thrombin generation. We hypothesized that the defect in
thrombin generation found in Pitpαﬂ/ﬂPf4-Cre+ plasma was due
to impaired IP3 production, as shown previously, which caused
low cytoplasmic calcium concentrations. To test this hypothesis,
we artiﬁcially raised the intracellular calcium concentration and
analyzed thrombin generation in PRP. We used ionophore
A23187, which transports extracellular calcium into the platelet
cytoplasm, as well as thapsigargin (TG), which can mobilize
intracellular calcium by an IP3-independent mechanism36, 37.
Both reagents have been demonstrated to activate platelets by
increasing cytoplasmic free calcium levels38–40. Both Pitpαﬂ/ﬂPf4-
Cre+ and Pitpαﬂ/ﬂPf4-Cre− PRP generated a similar level of
thrombin in the presence of the ionophore (10 µM) or TG (2 µM)
(Fig. 4f, g). This demonstrates that increasing the intracellular
calcium completely reverts the thrombin generation defect
induced by the loss of PITPα. Thus, PITPα within platelets
contributes to tumor metastasis through a signaling pathway that
involves IP3 formation, calcium inﬂux, phosphatidylserine
externalization, and thrombin generation. Together, these data
demonstrate that platelet PITPα is required for tumor-induced
thrombin generation in vitro and thrombus formation in vivo.
Platelet PITPα impairs the development of bronchus-
associated lymphoid tissue (BALT) hyperplasia. Although
Pitpαﬂ/ﬂPf4-Cre+ mice developed less platelet–tumor adhesions
than control mice during the ﬁrst few hours after tumor injection
(Fig. 3e–g), these results were not sufﬁcient to explain the long-
term effect of platelet PITPα on metastasis formation. To address
this issue, we analyzed the histology of tumor metastasis over
time. Two days after injection of the tumor cells, Pitpαﬂ/ﬂPf4-Cre+
mice developed strikingly hyperplastic BALT, a reaction that was
essentially absent in the controls (Fig. 5a–d). This hyperplasia
primarily consisted of hematopoietic-derived CD45R+ cells,
including T cells (CD3+), neutrophils (Ly-6G/C+), and natural
killer cells (NKp46+) (Fig. 5e–h). Thus, the initial stages of tumor
implantation in mice lacking platelet PITPα are associated with
inﬂammatory reactions that involve multiple types of leukocytes.
These data suggest that signals generated by PITPα in platelets
protect tumor cells from immune-mediated cytotoxicity, and
thereby enable tumor cell survival and propagation in both the
vasculature and in the tissues.
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Fig. 5 Loss of PITPα in platelets leads to a mucosal immune response. a–c Lung tissues were harvested 48 h after tumor injection and stained with H&E.
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Anticoagulation limits metastasis in Pitpαﬂ/ﬂPf4-Cre− mice.
Tissue factor-initiated coagulation has been demonstrated to
protect circulating tumor cells from elimination by immune
surveillance, which facilitates tumor metastasis, and B16F10
melanoma cells express high levels of tissue factor35. To under-
stand whether tumor cell-induced thrombin generation and ﬁbrin
formation mediated by PITPα in platelets contribute to metas-
tasis, we investigated the effects of a coagulation FVIIa inhibitor,
nematode anticoagulant protein c2 (NAPc2)41 injection on the
lung metastasis formation of B16F10 melanoma cells in vivo.
NAPc2 treatment in vivo inhibited lung metastasis when analyzed
2 weeks after injection in both genotypes. Anticoagulation
reduced metastasis formation and thrombocytopenia in both
genotypes (Fig. 6a, b). Furthermore, the effect of the PITPα
mutation in platelets was completely reverted by anticoagulation.
Histological analyses on lung tissue sections showed no sig-
niﬁcant thrombi formation at 3 h after injection, and no BALT
hyperplasia developed 48 h after injection (Supplementary Fig. 7).
Together, these data suggest that tumor-initiated coagulation
contributes to tumor metastasis in normal mice, and that this
effect can be impaired by either anticoagulation or by the PITPα
mutation in platelets.
To conﬁrm that the hemostatic process mediated by PITPα in
platelets contributes to the lung metastasis of intravenous injected
B16F10 melanoma cells, we investigated the impact of platelet
PITPα on the growth of tumor cells injected subcutaneously into
the ﬂanks of mice. The data show that the ﬂank tumors that
developed in Pitpαﬂ/ﬂPf4-Cre+ mice are similar to those that
developed in the control mice (Supplementary Fig. 8), demon-
strating that tumor cells grow at equivalent rates within the two
groups. Stated alternatively, since this model does not depend on
coagulation or mucosal immunity, there is no inﬂuence on tumor
formation by the loss of PITPα in platelets.
Discussion
Clinical observations and experimental animal models have
demonstrated that platelets support tumor metastasis formation.
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Our work conﬁrms these ﬁndings and expands on these previous
studies by establishing three additional and surprising observa-
tions: (1) Loss of PITPα in platelets causes only a partial deﬁcit in
phosphoinositide synthesis, yet it results in a major defect in
second messenger formation; (2) In spite of a major biochemical
defect in PITPα-null platelets, there is no obvious hemostatic
defect; and (3) The loss of PITPα in platelets leads to a defect in
tumor-induced thrombi formation that affects anti-tumor
immunity. The data shown in this study demonstrate that
PITPα-mediated phospholipid signaling in platelets contributes
to lung metastasis of intravenous injected tumor cells, but has no
signiﬁcant impact on hemostasis. Together, this demonstrates
that signaling pathways in platelets that are important for
hemostasis can be distinct from those pathways involved in non-
hemostatic functions.
Our data demonstrates that the loss of PITPα leads to the
moderate loss of PtdIns(4,5)P2, but curiously leads to a far greater
loss of its product, IP3. This suggests that PITPα is generating a
particular pool of PtdIns(4,5)P2 that is critical for the formation
of second messengers, such as IP3. Our previous work on PIP5KI
(the enzyme required for the ﬁnal step of PtdIns(4,5)P2 synthesis)
demonstrated that second messengers, including IP3, are gener-
ated exclusively from a pool of recently synthesized PtdIns(4,5)
P214. Together, these data show that in order to make second
messengers, platelets require a cooperative effect between PITPα
and PIP5KI to rapidly synthesize PtdIns(4,5)P2 in discrete
microdomains.
Since PITPα is required to generate normal amounts of phos-
phoinositides and second messengers within platelets, we antici-
pated ﬁnding defects in platelet-mediated hemostasis. However,
we were surprised to see that the substantial amount of phos-
phoinositide synthesis mediated by PITPα does not contribute to
pathways required for in vivo or ex vivo hemostasis. Our previous
work has demonstrated that the loss of speciﬁc pools of PtdIns
(4,5)P2 produced by PIP5KI within microdomains of platelets led
to discrete platelet defects. Similarly, we speculate that micro-
domains of PtdIns(4,5)P2 production, that are regulated by PITPα,
are tightly coupled to calcium levels in proximity to PS scram-
blases. In this scenario, the loss of PITPα would only diminish the
pool of phosphoinositides required for PS exposure, and with the
remaining pools of phosphoinositides, calcium and PS exposure
would be sufﬁcient for normal hemostatic function. Alternatively
stated, we hypothesize that PITPα contributes to the synthesis of
discrete pools of phosphoinositides within speciﬁc microdomains
in platelets, and these pools are not required for hemostasis.
We observed that platelets lacking PITPα do not efﬁciently
adhere to tumor cells in vivo and ex vivo by a mechanism that is
related to a deﬁciency in thrombin generation and ﬁbrin for-
mation. As shown in model (Fig. 6c), PITPα-null platelets cannot
form platelet–ﬁbrin complexes that usually envelope tumor cells.
This prevents thrombocytopenia in Pitpαﬂ/ﬂPf4-Cre+ mice fol-
lowing tumor cell injection. Without the platelet–ﬁbrin shroud
surrounding the tumors, these malignant cells are more vulner-
able to mucosal immune responses that block tumor cell
implantation. The evidence shown in this study demonstrates that
impaired IP3-induced calcium release is the critical mechanism
that prevents metastasis in Pitpαﬂ/ﬂPf4-Cre+ mice. Inﬂux of
intracellular calcium activates membrane scramblase activity and
exposes phosphatidylserine on the platelet surface. This facilitates
tenase and prothrombinase complexes that lead to thrombin
generation and ﬁbrin polymerization around the tumor cells.
Together, these ﬁndings demonstrate that PITPα-mediated sig-
naling in platelets indirectly augments the early stages of tumor
dissemination.
While dysfunction of PITPα-null platelets seems to be the
major contributor for decreased metastasis, it is important to note
that there was a 15% decrease in platelet count for these mice.
Both clinically and experimentally, this small degree of throm-
bocytopenia was not found to be critical for hemostasis. In
addition, the data in this study demonstrate that the mild
thrombocytopenia in Pitpαﬂ/ﬂPf4-Cre+ mice also did not con-
tribute to the dissemination of tumors. This is based on the
observation of the pronounced acute thrombocytopenia in con-
trol mice after tumor injection that was not evident in the Pitpαﬂ/
ﬂPf4-Cre+ mice (Fig. 3d). Consequently, when compared to the
control mice, there were actually more platelets in the circulation
of the Pitpαﬂ/ﬂPf4-Cre+ mice during the critical early hours after
tumor injection even though the metastasis defect was occurring.
Thus, the inability of the tumors to metastasize could not be due
to mild basal thrombocytopenia in the Pitpαﬂ/ﬂPf4-Cre+ mice, but
rather due to an intrinsic defect of platelet function.
In 1865, Dr. Armand Trousseau ﬁrst described the association
between cancer and thrombosis42. Ironically, years later, Dr.
Trousseau himself tragically succumbed to widespread throm-
bosis caused by his pancreatic cancer. Tumor cells are known to
activate platelets, which in turn facilitates tumor implantation,
adhesion, propagation, and invasion of the immune system. Our
study demonstrates the vital role of platelet phosphoinositide
signaling in the dissemination of cancer. Furthermore, this work
also clearly distinguishes the platelet signaling processes required
for hemostasis from those processes that augment metastasis
formation. Additional studies will be required to determine
whether targeting speciﬁc non-hemostatic platelet signaling
pathways could be exploited in the development of clinical
therapeutics.
Methods
Mice. Animals were maintained on standard chow and tap water. Animal proce-
dures and experiments were approved by the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Pitpα conditional mice, Flp mice,
and Pf4-Cre transgenic mice were used in this study. The genetic background of all
mice used was C57BL6, and both sexes of mice were used for all experiments unless
noted in the methods. The ages of mice used were between 8 and 20 weeks. To
produce mice with conditional targeting of the murine Pitpα gene, a 10.8 kb
genomic fragment was identiﬁed in a C57BL/6 (RPCI23: 105D24) BAC library and
then cloned into the pSP72 vector (Promega). The “long homology arm” was 7.42
kb in length, and the “short homology arm” was 1.83 kb in length. The pGK-gb2
loxP/FRT Neo cassette was inserted into a region that corresponded to the 3′ end of
exon 10, and an additional loxP site was inserted into a region that corresponded to
the 5′ end of exon 8. Therefore, this targeting design removed a 1.55 kb region of
Pitpα genomic DNA that included exons 8, 9, and 10. The targeting vector was
conﬁrmed by PCR, restriction analysis, and sequencing after each modiﬁcation
step. Additional conﬁrmation of the ﬁnal clones was performed by Southern
blotting analysis.
The neomycin cassette ﬂanked by FRT sites was removed by crossing with
ﬂippase (FLP) transgenic mice (Jackson Lab). Transgenic mice that contain Cre
recombinase driven by platelet factor-4 promoter (Pf4-Cre) (obtained as a generous
gift from Radek Skoda, of the University of Basel, Switzerland) were further crossed
with Pitpα conditional mice to induce the deletion of PITPα, speciﬁcally in platelets
and in megakaryocytes.
Genomic DNA isolated from tail biopsies was used for the genotyping of the
conditional alleles of the Pitpα gene by PCR, using forward primer
(5′-GAACAAGAAACTATCCAGCAGACAGACT-3′) and reverse primer
(5′-CTTCCTCTGCCTTGTAATCCTGAG-3′).
Antibodies and reagents. Antibodies used in this study were as follows: mouse
anti-human PITPα (5F12) (Santa Cruz Biotechnology, sc-13569; 1:400); rabbit
anti-human PITPβ (Abcam, ab83795; 1:1000); rabbit anti-β-Actin (Cell Signaling,
#4970; 1:2500); goat anti-mouse TRP1 (A-20) (Santa Cruz Biotechnology,
sc-10446; 1:150); rat anti-mouse CD41 (MWReg30) (Santa Cruz Biotechnology,
sc-19963; 1:50); rat Anti-CD41 F(ab)2 fragments (MWReg30) (BD Biosciences,
custom order; 0.12 µg/g body weight); anti-P-selectin (RB40.34) (BD Bioscience,
custom order; 0.2 µg/g body weight); rat anti-mouse neutrophils (Ly-6G/C) (Santa
Cruz Biotechnology, sc-59338; 1:50); rat anti-mouse CD45R (RA3-6B2) (Santa
Cruz Biotechnology, sc-19597; 1:150); rat anti-mouse CD3 (17A2) (BioLegend,
100212; 1:150); rat anti-mouse CD335 (NKp46) (BioLegend, 137603; 1:120); anti-
mouse ﬁbrin (clone 59D8, gift from Dr. Rodney M. Camire of Children Hospital of
Philadelphia, 1:500); PE-anti-mouse/rat CD62P P-selectin (RMP-1) (BioLegend,
148305; 1:150); PE-labeled rat anti-mouse integrin αIIbβ3 antibody (JON/A)
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(Emfret Analytics, #M023-2; 1:20); ImmPRESS reagent Anti-Rat Ig (MP-7404,
Vector Laboratories); and ImmPRESS reagent anti-Goat Ig (MP-7405, Vector
Laboratories).
Reagents used in this study were: Fura-2/AM (Thermo Fisher Scientiﬁc, F1221);
Pluronic F-127 (Sigma, P2443); puriﬁed recombinant human PITPα and PITPβ
proteins (a generous gift from Dr. Shamshad Cockcroft of University College
London); CHRONO-LUME luciferase Luciferin (CHRONO-LOG, #393);
Thrombin (CHRONO-LOG, #386); Collagen (Sigma, #885-1); Inositol-1,4,5-
triphosphate [3H] radioreceptor assay kit (PerkinElmer Life Science, #NEK064);
and Phosphorus-32 Radionuclide, 2 mCi (PerkinElmer Life Science,
#NEX053H002MC).
Washed platelet preparation and aggregation. Washed platelets were prepared
from blood collected from the inferior vena cava of anesthetized mice in the
presence of 6× acid citrate dextrose buffer (ACD, pH 4.4, 85 mM sodium citrate
dihydrate, 66.6 mM citric acid, 111 mM dextrose)14. All procedures were done at
room temperature. PRP was separated by centrifugation of blood at 200 × g for 10
min. PRP was incubated with 1 μM prostaglandin E1 (PGE1) for 10 min. Platelets
were isolated by centrifugation of PRP at 800 × g for 10 min to remove PPP. The
pellet was resuspended in Hepes-Tyrode buffer pH 7.4 (134 mM NaCl, 3 mM KCl,
0.3 mM NaH2PO4, 12 mM NaHCO3, 2 mM MgCl2, 5 mM Hepes, 5 mM glucose,
and 0.35% BSA). For the aggregation assay, washed platelets were adjusted to 2 ×
108 platelets/ml by using Hepes-Tyrode’s buffer and supplemented with 1 mM
CaCl2. The aggregation was measured by the turbidometric method at 37 °C in the
presence of CHRONO-LUME luciferase in a Lumi-Dual aggregometer (Chrono-
Log).
Quantitation of platelet phosphoinositides. Platelets were prepared as described
above and were washed once with modiﬁed Tyrode’s buffer (pH 6.5) (134 mM
NaCl, 3 mM KCl, 0.3 mM NaH2PO4, 12 mM NaHCO3, 2 mM MgCl2, 1 mM
EGTA, 1 μM PGE1, 5 mM Hepes, 5 mM glucose, and 0.35% BSA). The platelets
were then resuspended to 1 × 109/ml by using modiﬁed Tyrode’s buffer (pH 7.4)
without PGE1, EGTA, and NaH2PO4. The platelets were supplemented with 1 mM
CaCl2. Platelet suspensions (0.5 ml) were incubated (phosphate-starved) at 37 °C
for 30 min and then supplemented with 0.5 mCi of 32P for 90 min. The incor-
poration of 32P was halted by the addition of 50 μl of ice-cold HCl and 1 volume of
methanol:chloroform (1:1) on ice. Mixtures were vortexed for 1 min to extract total
phospholipids and were centrifuged at 2000 × g for 3 min. The chloroform phase
was isolated, and the remaining aqueous phase was extracted again with chloro-
form. The two chloroform phases were combined and evaporated under N2 ﬂow.
The dried residue was resuspended in 25 μl of ice-cold chloroform:methanol (1:1).
Total phospholipids in the chloroform/methanol solution were fractionated by
TLC and analyzed as described14. The levels of each phosphoinositide were
quantiﬁed by JustTLC software (Sweday).
Quantitation of IP3 formation in platelets. The washed platelets were prepared as
described above, and their density was adjusted to 7–10 × 108/ml in Hepes-Tyr-
ode’s buffer that was supplemented with 1 mM CaCl2. Platelets in 200 μl aliquots
were activated by thrombin at 1 U/ml for indicated times. The reaction was halted
by adding 40 μl of ice-cold 20% perchloric acid, and incubated for 20 min to lyse
the cells. The cellular debris was removed by centrifugation at 2000 × g for 15 min,
and the supernatant was adjusted to pH 7.5 by the addition of KOH, and then
clariﬁed again at 2000 × g for 15 min at 4 °C before harvesting the ﬁnal supernatant.
Quantitation of IP3 was performed by using the inositol-1,4,5-trisphosphate [3H]
radio-receptor assay kit (PerkinElmer), according to the manufacturer’s protocol.
In vivo thrombosis tail bleeding time. The distal 5 mm tail segment of 5–6-
weeks-old mice were amputated with a scalpel after administration of anesthesia.
The tails were immediately immersed in 37 °C saline. The bleeding time was
presented as the sum of bleeding within 15 min of observation, including re-
bleeding. The time of complete cessation of blood ﬂow (i.e., no blood ﬂow for 1
min) was noted. The lost blood was collected in PBS and the blood cells were lysed
in Red Blood Cell Lysing buffer (Sigma-Aldrich, R7757) to collect protein lysate.
The blood volume was represented by the measurement of hemoglobin in the
lysate of lost red blood cells43.
FeCl3-induced carotid thrombosis formation. Mice were anesthetized using 2%
isoﬂurane gas in oxygen. A midline incision was made in the neck, and the right
carotid artery was exposed by blunt dissection. Whatman ﬁlter paper (#1, 1 mm2)
soaked in 7.5% FeCl3 was applied to the exposed artery for 2 min. After removal of
the ﬁlter paper, the artery was washed with PBS, and blood ﬂow was recorded using
a small animal blood ﬂow meter (model T106, Transonic Systems Inc., Ithaca, NY)
for 30 min. The time to full occlusion is reported.
Laser-induced in vivo thrombosis. Male mice 8–12 weeks of age were anesthe-
tized via intraperitoneal injection of sodium pentobarbital (90 mg/kg)30. A cannula
was introduced into the jugular vein for the delivery of antibodies and additional
anesthetic as needed. The cremaster muscle was exteriorized, cleaned of connective
tissue, opened, and spread ﬂat on the glass coverslip of a custom-built chamber for
viewing by intravital microscopy. The cremaster preparation was continuously
superfused with bicarbonate buffer warmed to 36.5 °C and bubbled with 95% N2/
5% CO2. The cremaster microcirculation was visualized using an Olympus
BX61WI upright microscope with a 60× (0.9 NA) water immersion objective,
coupled to a Yokogawa CSU-X1 spinning disk confocal scanner. Laser injury was
induced with a pulsed nitrogen dye laser (SRS NL100, 440 nm, 55-65% power
setting) focused on the vessel wall by the microscope objective. The laser ﬁred at
the vessel wall until only a small number of red blood cells exited the lumen of the
vessel (1–10 laser pulses). Confocal ﬂuorescence images were acquired using a
CoolSnap HQ CCD digital camera (Photometrics, Tucson, AZ). The microscope,
confocal scanner, lasers, and camera were all controlled and synchronized using
Slidebook 5.0 image acquisition and analysis software (Intelligent Imaging Inno-
vations). Arterioles (30–40 µm diameter) with unperturbed blood ﬂow were
selected for study. Anti-CD41 F(ab)2 fragments (0.12 µg/g body weight; clone
MWReg30, BD Bioscience) and anti-P-selectin (0.2 µg/g body weight; clone
RB40.34, BD Bioscience) antibodies were labeled with Alexa ﬂuor dye monoclonal
antibody labeling kits (Alexa-488, Alexa-568, and Alexa-647), according to the
manufacturer’s instructions (Invitrogen).
Quantitative analysis of the lung metastasis of B16F10 melanomas. The
B16F10 cell line was obtained from the American Type Culture Collection
(Manassas, VA, USA) and cultured in Dulbecco’s Modiﬁed Eagle’s Medium that
was supplemented with 10% v/v, fetal calf serum, and 300 μg/ml L-glutamine.
Tumor cells from a mid-log phase culture were collected by brief exposure to 0.05%
trypsin/EDTA solution (Invitrogen), washed twice with PBS, and then re-
suspended in PBS at a density of 5 × 106/ml. A 200 μl aliquot of B16F10 tumor cells
(1 × 105 cells) with or without FVIIa inhibitor NAPc2 (150 nM) was injected
through the tail veins of the mice. At various time intervals after injection, the mice
were euthanized, and perfused with 10 ml ice-cold PBS that was supplemented with
4% formalin. The lungs were carefully removed, dissected free of other connective
tissues, and then ﬁxed in 10% formalin. The tumor nodules on the lung surface
were counted under microscopy, and the lung was weighed.
Quantiﬁcation of thrombus formation. Tumor injection-induced thrombi for-
mations in lung tissue were quantiﬁed on parafﬁn-embedded tissue sections. Three
slides across 300 μm were collected in each sample at 100 μm intervals. Platelet-rich
thrombi were identiﬁed by immunohistochemistry staining of CD41, and the
numbers either in the vasculature or within the pulmonary tissue were counted
under the microscope at 10× magniﬁcation from three randomly selected optical
ﬁelds.
Immunohistochemistry. The slides were de-parafﬁnized with xylene, dehydrated
in ethanol, and then treated with 20 μg/ml proteinase K in TE buffer, pH 8.0
containing 0.5% triton X-100 for 15 min at 37 °C. The slides were then treated with
3% H2O2 for 15 min to block endogenous peroxidase, and then treated with 2.5%
normal serum for 60 min to block non-speciﬁc antibody binding. The tissue sec-
tions were stained with primary antibodies and peroxidase secondary antibody as
instructed by the ImmPRESS reagent kit (Vector Laboratories). The signals were
visualized by developing with DAB as indicated by the ImmPact DAB peroxidase
substrate kit (Vector Laboratories).
Immunoblotting. Washed platelets were prepared as described above. After ﬁnal
centrifugation, the platelet pellet was resuspended in ice-cold RIPA buffer (Sigma-
Aldrich, R0278) supplemented with cOmplete protease inhibitor (Roche,
11836170001) to lyse the platelets. Platelet lysate protein concentration was mea-
sured with BCA kit (Thermo Scientiﬁc Pierce, 23225) and adjusted with RIPA
buffer so that each sample had a total of 50 µg of protein. NuPage LDS Sample
buffer (Invitrogen, NP0008) and NuPage reducing agent (Invitrogen, NP0004)
were added to each sample aliquot. Samples were loaded on a NuPage 4–12% Bis-
Tris protein gel (Invitrogen, NP0321) and run in reducing conditions with a
NuPage MOPS SDS running buffer (Invitrogen, NP0001). Gels were then blotted
onto polyvinylidene ﬂuoride membrane (Invitrogen, LC2002). After blotting,
membranes were blocked with 5% Blotting Grade Blocker Non-Fat Dry Milk
(BioRad #1706404XTU) in 0.1% Tween/TBS (BioRad #1706435, #1662404) for 1 h.
Blots were incubated with primary antibody in blocking buffer overnight at 4 °C.
Afterwards, blots were incubated with secondary antibody conjugated with HRP
(anti-rabbit or anti-mouse; Cell Signaling Technology, #7074, #7076) for 1 h at
room temperature. Blots were washed several times with 0.1% Tween/TBS between
each step. Blots were developed with ECL Prime Western Blotting detection
reagent (GE Healthcare Life Sciences, RPN2232), exposed on autoradiographic ﬁlm
(Denville Scientiﬁc, E3018), and digitized on a scanner. Uncropped immunoblots
are shown in Supplementary Fig. 9.
Annexin V binding on agonist-activated platelets. The binding of Annexin V on
platelets was quantiﬁed by ﬂow cytometry44. Whole blood was collected from the
inferior vena cava and diluted at 1:100 in the ﬁnal resuspension buffer (pH 7.4, 134
mM NaCl, 3 mM KCl, 0.3 mM NaH2PO4, 12 mM NaHCO3, 2 mM MgCl2, 5 mM
Hepes, 5 mM glucose, and 0.35% BSA) that contained 2 mM CaCl2. GPRP (Sigma,
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Cat# G1895-25mg) at a ﬁnal concentration of 1 mM was supplemented to prevent
ﬁbrin polymerization before the stimulation of agonists. Diluted platelets in whole
blood were stimulated with an agonist combination that contained
5 μg/ml collagen and 0.1 U/ml thrombin at 37 °C for 10 min. The samples were
then labeled with 50 nM Annexin V-Alexa-FITC antibody (BD Biosciences,
#556420; 1:20) and CD41a-PE antibody (BD Biosciences, #558040; 1:100) to
identify platelets at room temperature for 30 min. The binding was analyzed by
ﬂow cytometry (BD FACSCanto II Flow Cytometry System) gating on the CD41-
positive cell population.
Flow cytometry. After collecting platelets, as described above, cells were diluted to
107 cells/ml. Platelets (100 µl) were stained with PE-labeled rat anti-mouse integrin
αIIbβ3 antibody (JON/A) (Emfret Analytics, #M023-2; 1:20) for 30 min. The tubes
were washed with 0.1% BSA in PBS and centrifuged to remove non-bound anti-
body and resuspended in 0.1% BSA in PBS before analyzing cells on FACSCanto II
Flow Cytometry System (BD Bioscience). Flow cytometry was assisted by the Flow
Cytometry Core Laboratory at Children’s Hospital of Philadelphia core facility.
Thrombin generation assay. Thrombin generation in platelets was measured in
the automated analyzer CEVERON alpha with a TGA module (TECHNO-
THROMBIN TGA, DiaPharma) based on monitoring the formation of thrombin
by means of a ﬂuorogenic substrate upon activation of the coagulation cascade by
tissue factor. Blood was withdrawn in the presence of 6× ACD, and PRP was
collected after centrifuging at 200 × g for 10 min. The samples were further cen-
trifuged for 15 min at 1500 × g to collect the PPP as controls. Platelets in PRP were
counted, and the concentration was adjusted to 5 × 108/ml. For each measurement,
40 μl of each sample, 10 μl of TGA trigger B16F10 tumor cells (1 × 107/ml), and
agonists were mixed in 96-well plates in duplicate. The samples were maintained at
33 °C. Once 50 μl of TGA substrate was added into each well, measurements were
obtained at 30 s intervals for 90 min. Thrombin generation was calculated by the
manufacturer’s software utilizing a standard thrombin calibration curve that was
derived separately.
Quantiﬁcation of BALT hyperplasia. The BALT hyperplasia on each section was
manually counted under microscope at 4× magniﬁcation after H&E staining. One
section per 100 μm tissue was used for the quantiﬁcation, and a total of three slides
across 300 μm were collected.
Platelet counts. Peripheral blood was collected through retro-orbital puncture of
Pitpαﬂ/ﬂPf4-Cre+ and Pitpαﬂ/ﬂPf4-Cre− mice matched for age and gender. Com-
plete blood counts (CBC) and mean platelet volumes were analyzed using a Drew
Hemavet Hemacytometer (HV1700).
Intracellular calcium ﬂux measurement. PRP was collected and platelets were
suspended to 5 × 108/ml in Tyrode’s buffer without calcium. Apyrase and PGE-1
were added to prevent aggregation. Platelets were loaded with fura-2/AM (5 μM) in
the presence of Pluronic F-127 (0.2 μg/ml) for 15 min at 37 °C, then washed and
resuspended in Tyrode’s buffer without calcium. Stirred platelets were activated
with thrombin, and ﬂuorescence was measured with an Aminco Bowman Series 2
Luminescence spectrophotometer45. The excitation wavelengths alternated
between 340 and 380 nm, and emission was measured at 510 nm. Each measure-
ment was calibrated using Triton X-100 and EGTA. Fura-2 Kd= 224 nM. Maximal
increase in [Ca2+] was determined by subtracting baseline before stimulus from
peak.
Fibrin staining. Fibrin production in thrombi was stained by rapid microwave
phosphotungstic acid hematoxylin (P.T.A.H) (American MasterTech) on 6 μm
parafﬁn-embedded sections of lung tissue. De-parafﬁnized slides were incubated in
microwave heated 10% zinc chloride solution for 15 min, washed in running tap
water, and followed by incubation in microwave heated 5% ferric ammonium
sulfate solution for 2 min. After washing with water, the slides were further stained
for 30 min in P.T.A.H that had been pre-heated in a microwave for 10–20 s. The
slides were dehydrated in 95% alcohol and then covered with a mounting slip prior
to microscope analysis.
Lung metastatic analysis of intravenous injected LLC. LLC cell line was
obtained from the American Type Culture Collection (Manassas, VA, USA, #CRL-
1642) and cultured in Dulbecco’s Modiﬁed Eagle’s Medium that was supplemented
with 10% v/v, fetal calf serum (Sigma Aldrich), and 300 μg/ml L-glutamine
(Invitrogen). Tumor cells from a mid-log phase culture were collected by brief
exposure to 0.05% trypsin/EDTA solution, washed twice with PBS, and then re-
suspended in PBS at a density of 5 × 106/ml. A 200 μl aliquot of tumor cells (1 × 105
cells) was injected through the tail vein of the mice. The mice were euthanized at
3 weeks after injection, and perfused with 10 ml ice-cold PBS that was supple-
mented with 4% formalin. The lungs were carefully removed, dissected free of other
connective tissues, and then ﬁxed in 10% formalin. The tumor nodules on the lung
surface were counted under microscopy. Some of the lungs were parafﬁn-
embedded and sectioned at 6 µm for H&E staining. The tumors on tissue sections
were counted under microscope at 10× magniﬁcation across 300 µm of each lung
and presented as average number of tumors per section.
Flank tumors. B16F10 melanoma cells were utilized for ﬂank tumor growth
measurement. Tumor cells at 1 × 106/ml in PBS were subcutaneously injected. Two
weeks after injection, mice were euthanized and the tumors were dissected,
weighed, and ﬁxed in 10% formalin.
Statistics. Two-tailed unpaired or paired Student’s t-tests were applied for the
comparison of two means for all analyses, except for the tail bleeding times and
intravital assay, which utilized the Mann–Whitney test. P-values of less than 0.05
were considered statistically signiﬁcant.
Data availability. All relevant data are available from the authors upon reasonable
request.
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